

A new mindset

We want GSK to be recognised around the world by all stakeholders as a company with the highest ethical standards.

We want to be a company that is forward looking, innovative and willing to try new approaches and partnerships; a company that is constantly looking for new ways to increase access to our medicines and vaccines, especially for those least able to pay.

We have made significant progress in helping to address global healthcare challenges. For example, we are moving closer to finding a malaria vaccine and eliminating lymphatic filariasis, a debilitating disease.

But we know that we can do more. We will find ways to make our medicines more affordable and to boost research into neglected diseases. We will partner with others to support healthcare infrastructure development where it is needed most.

It is time for a new mindset in our industry and a new contract with society. With the support of other pharmaceutical companies and partners outside industry, I believe significant improvements in human health really can be achieved.

To find out more about GSK please go to www.gsk.com/responsibility



Andrew Witty
Chief Executive Officer

For patients

Improving healthcare worldwide

Every year millions of people die because they cannot afford essential medicines or because no effective treatments exist.

We research new medicines and vaccines for the most serious diseases and adjust our prices to make these more affordable to the developing world.

Making progress on pricing

Starting in 2009 we will reduce our prices for patented medicines in Least Developed Countries (LDCs) so that they are no higher than 25% of the price in the developed world. Where possible we will reduce our prices further. We are also exploring a more flexible approach to intellectual property rights for treatments for neglected diseases in LDCs.

Our commitment to preferential pricing means we already offer our AIDS and malaria medicines at not-for-profit prices in the world's poorest countries. We also supply our vaccines to organisations such as GAVI and UNICEF at preferential prices, typically 10-20% of the prices in developed countries.

We will also review prices for middle-income countries, where there is wealth but also significant poverty. We want to set our prices so they will more closely reflect a country's ability to pay.

Pricing is also an issue in the developed world, where healthcare costs are rising. We are committed to working in partnership to find solutions where industry is rewarded for innovation, healthcare payers get value-for-money and more patients receive the medicines they need.

Taking on the biggest killer

Malaria kills over one million people a year worldwide, mostly children in sub-Saharan Africa. Millions more suffer serious and debilitating illness.

GSK is at the forefront of the battle against malaria. We have been working on a malaria vaccine for over two decades. In partnership with the PATH Malaria Vaccine Initiative, a non-profit research organisation, we are now close to creating the world's first vaccine for the disease.

Trials have shown that our candidate vaccine protects children living in the most high risk areas in Africa and it can be administered alongside other vaccines in existing immunisation programmes. If trials are successful the vaccine could be introduced in 2012 for children aged 5-17 months, with full availability in 2014 following approval for infants, potentially saving hundreds of thousands of lives each year.

We have invested over \$300 million in research for the malaria vaccine which has been assisted by an additional \$100 million of support from the Bill and Melinda Gates Foundation.

Read more online about our efforts to tackle the healthcare crisis. www.gsk.com/responsibility



Key facts 2008

Leader

Recognised as the leader in the Access to Medicines Index, an independent NGO/investor ranking of pharmaceutical companies

80%

Supplied 1.1 billion vaccine doses for prevention of serious diseases, nearly 80% to the developing world

64

Reduced our not-for-profit prices for our HIV/AIDS medicines and anti-malarials for the fifth time since 1997; offered to sub-Saharan Africa and Least Developed Countries, 64 in total

349m

349 million anti-retroviral tablets supplied to the developing world at preferential prices, includes 279 million supplied by generic manufacturers licensed by GSK

£124m

Community investment valued at £124m

£3.7bn

Expenditure of £3.7 billion and 15,000 people employed in R&D

171

171 energy saving projects completed in 2008; expected to save more than 40,000 tonnes of CO₂ equivalent emissions annually

12

R&D investment into 12 diseases of particular importance for the developing world

20%

Committed in 2009 to use 20% of profits from selling medicines in Least Developed Countries, £1-£2 million, to strengthen healthcare infrastructure

600m

Committed to double our manufacturing capacity of our donated lymphatic filariasis treatment albendazole to 600 million tablets per year

For communities

We help communities around the world prevent disease and improve healthcare. In 2008 our community investment, including medicines and money, was £124 million.

Eliminating disease

Since smallpox was eradicated in 1979, no other infectious disease has been successfully eliminated. We are determined to change this.

We are donating albendazole, our anti-parasitic medicine, to eliminate lymphatic filariasis (LF), a debilitating and disfiguring disease. LF, which is transmitted by mosquitoes, is one of the world's leading causes of permanent disability.

Since 1998 we have donated over one billion albendazole tablets and over 180 million people have been treated. We estimate that more than 66 million babies born in treated regions have been spared the risk of contracting LF.

With more than one billion people in over 80 tropical countries at risk of infection there is much more to do. We are scaling up our manufacturing capacity in Nashik, western India, which will enable us to double our annual donations of albendazole tablets to 600 million by next year.

Read more online about how we are helping communities to combat disease.

 www.gsk.com/responsibility



For the environment



We are becoming a more sustainable business, cutting our climate impact, resource use and waste. This helps to protect the future wellbeing of communities, the environment and our company.

Pursuing sustainability

Our carbon footprint is significant, seven million tonnes of CO₂ in 2008. Tackling climate change is a priority. We will reduce our energy use and climate impact by 45% per unit of sales by 2015 by making our buildings, equipment and transport more efficient and buying and generating renewable electricity.

Beyond this we are reducing the environmental impacts of our products throughout their lifecycle. Our *Ribena* blackcurrant drink is one example. We help the blackcurrant farmers to preserve biodiversity on their farms benefiting local wildlife, and to reduce the climate impact of growing the berries. We are working towards zero waste to landfill from our *Ribena* manufacturing sites and have introduced Europe's first 100% recycled and recyclable bottle. We are testing reverse vending machines to encourage people to recycle their used *Ribena* bottles.

In our pharmaceuticals business we have a target to double the manufacturing efficiency of all new products.

Read more online about how we are cutting the environmental impacts of our business and products.

 www.gsk.com/responsibility



Find out more at www.gsk.com

We want to work in a way that reflects our values and the expectations of our stakeholders. Ethical, social and environmental considerations are integral to our business decision making.

Our full report covers key responsibility issues including access to medicines, research and business ethics, the environment, employment practices, stakeholder engagement and our investment in communities.

Find out more about our approach to corporate responsibility in our 2008 report at

www.gsk.com/responsibility

Brand names appearing in italics throughout this publication are trademarks either owned by and/or licensed to GSK or associated companies. Printed in the UK on paper produced from 100% post-consumer waste. Pulp is bleached using a totally chlorine free process.



Do more, feel better, live longer

Our responsibility